guest ::
| Home > Publications database > Thyroid hormones and epithelial ovarian cancer risk and survival: results from the EPIC study. > print |
| Home > Publications database > Thyroid hormones and epithelial ovarian cancer risk and survival: results from the EPIC study. > print |
| 001 | 303508 | ||
| 005 | 20250816200218.0 | ||
| 024 | 7 | _ | |a 10.1093/jnci/djaf222 |2 doi |
| 024 | 7 | _ | |a pmid:40811636 |2 pmid |
| 024 | 7 | _ | |a 0027-8874 |2 ISSN |
| 024 | 7 | _ | |a 1460-2105 |2 ISSN |
| 024 | 7 | _ | |a 1475-4029 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-01698 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Majidi, Azam |b 0 |
| 245 | _ | _ | |a Thyroid hormones and epithelial ovarian cancer risk and survival: results from the EPIC study. |
| 260 | _ | _ | |a Oxford |c 2025 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1755266564_8664 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Thyroid-stimulating hormone (TSH) and thyroid hormones (free triiodothyronine[fT3] and free thyroxine[fT4]) may influence cancer outcomes, but evidence for ovarian cancer is limited.We conducted a nested case-control study comparing 578 epithelial ovarian cancer (EOC) cases to matched controls within the European Prospective Investigation into Cancer and Nutrition (EPIC). To examine associations between circulating TSH, fT3, and fT4 levels and EOC risk, we estimated risk ratios (RRs) and 95% confidence intervals (CIs) per standard deviation (SD) using conditional logistic regression. Among cases, we evaluated all-cause and EOC-specific survival by pre-diagnostic hormone levels. Hazard ratios (HRs) and 95% CIs were calculated using multivariable Cox regression. We also estimated covariate-adjusted restricted mean survival time (RMST) and survival probabilities at 5 and 10 years.Thyroid hormones were not associated with EOC risk (RR[95%CI] per SD increase: TSH = 0.99[0.87-1.12]), fT3 = 1.12[0.70-1.79], and fT4 = 1.08[0.56-2.07]) levels. However, higher TSH levels were associated with better survival (HR[95%CI] per SD: all-cause death = 0.90[0.82-0.99], EOC-specific = 0.88[0.79-0.97]), while higher fT4 levels were associated with worse survival (all-cause = 1.10[1.00-1.22], EOC-specific = 1.17[1.05-1.30]), but no association for fT3. RMST and survival probabilities showed similar patterns: for TSH , 10-year RMST and survival increased from 5.3 years and 42.2% in Q1 to 6.4 years and 50.7% in (Quartile[Q]4). Conversely, for fT4, 10-year RMST declined from 5.6 years (Q1) to 5.1 years Q4, and survival from 46.3% to 37.8%.TSH and Thyroid hormones might not affect ovarian cancer risk. However, high fT4 and low TSH concentrations may be associated with poorer survival. Further evaluation is suggested in other populations. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Rinaldi, Sabina |b 1 |
| 700 | 1 | _ | |a Biessy, Carine |b 2 |
| 700 | 1 | _ | |a Vozar, Beatrice |b 3 |
| 700 | 1 | _ | |a Truong, Therese |b 4 |
| 700 | 1 | _ | |a Turzanski Fortner, Renée |0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2 |b 5 |u dkfz |
| 700 | 1 | _ | |a Le Cornet, Charlotte |0 P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6 |b 6 |u dkfz |
| 700 | 1 | _ | |a Schulze, Matthias B |b 7 |
| 700 | 1 | _ | |a Panico, Camilla |b 8 |
| 700 | 1 | _ | |a Tumino, Rosario |b 9 |
| 700 | 1 | _ | |a Masala, Giovanna |b 10 |
| 700 | 1 | _ | |a Ricceri, Fulvio |b 11 |
| 700 | 1 | _ | |a Vener, Claudia |b 12 |
| 700 | 1 | _ | |a Sánchez, Maria-José |b 13 |
| 700 | 1 | _ | |a Zamora-Ros, Raúl |b 14 |
| 700 | 1 | _ | |a Crous-Bou, Marta |b 15 |
| 700 | 1 | _ | |a Colorado-Yohar, Sandra M |b 16 |
| 700 | 1 | _ | |a Guevara, Marcela |b 17 |
| 700 | 1 | _ | |a Israelsson, Pernilla |b 18 |
| 700 | 1 | _ | |a Travis, Ruth |b 19 |
| 700 | 1 | _ | |a Riboli, Elio |b 20 |
| 700 | 1 | _ | |a Fournier, Agnès |b 21 |
| 700 | 1 | _ | |a Dossus, Laure |b 22 |
| 773 | _ | _ | |a 10.1093/jnci/djaf222 |g p. djaf222 |0 PERI:(DE-600)1465951-7 |p nn |t Journal of the National Cancer Institute |v nn |y 2025 |x 0027-8874 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:303508 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-28 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b JNCI-J NATL CANCER I : 2022 |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-28 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-28 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-28 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b JNCI-J NATL CANCER I : 2022 |d 2024-12-28 |
| 920 | 1 | _ | |0 I:(DE-He78)C180-20160331 |k C180 |l Krebsepidemiologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C180-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|